Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 3:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: OCA 10 mg Clear all
Completed Phase 2 Interventional Results available

Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL)

NCT02633956
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Obeticholic Acid, Atorvastatin, Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
22
States / cities
Phoenix, Arizona • La Jolla, California • Rialto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Oct 18, 2026, 3:12 PM EDT
Completed Not applicable Interventional

The Effects of Lutein and Zeaxanthin Supplementation on Vision in Patients With Albinism

NCT02200263
View directory record Official record
Conditions
Ocular Albinism (OA), Oculocutaneous Albinism (OCA)
Interventions
Lutein plus Zeaxanthin, Placebo
Dietary Supplement
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 28, 2018 · Synced Oct 18, 2026, 3:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Heavy Alcohol Consumption on Farnesoid X Receptor (FXR) Signaling

NCT02654236
View directory record Official record
Conditions
Alcohol Consumption
Interventions
Placebo, 10 mg Obeticholic Acid (OCA)
Drug
Lead sponsor
Suthat Liangpunsakul
Other
Eligibility
21 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Oct 18, 2026, 3:12 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis

NCT01865812
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Obeticholic Acid
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
La Jolla, California • Sacramento, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Oct 18, 2026, 3:12 PM EDT
Withdrawn No phase listed Observational

A Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients

NCT05293938
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Obeticholic Acid 5 MG, Obeticholic Acid 10 MG, Standard of Care: UDCA
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 18, 2026, 3:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Food on Pharmacokinetics of Obeticholic Acid (OCA)

NCT01914562
View directory record Official record
Conditions
Healthy
Interventions
OCA 10 mg, OCA 25 mg
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 8, 2014 · Synced Oct 18, 2026, 3:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose and Multiple Dose Trial to Assess Pharmacokinetics of Obeticholic Acid (OCA)

NCT01933503
View directory record Official record
Conditions
Healthy
Interventions
OCA 5 mg, OCA 10 mg, OCA 25 mg
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 5, 2013 · Synced Oct 18, 2026, 3:12 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis

NCT01473524
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Obeticholic Acid (OCA), Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
15
States / cities
Sacramento, California • San Diego, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Oct 18, 2026, 3:12 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis

NCT03439254
View directory record Official record
Conditions
Compensated Cirrhosis, Nonalcoholic Steatohepatitis
Interventions
Obeticholic acid (10 mg), Obeticholic acid (10 mg to 25 mg), Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
919 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
120
States / cities
Dothan, Alabama • Madison, Alabama • Chandler, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 18, 2026, 3:12 PM EDT
Completed Phase 2 Interventional Results available

Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC)

NCT00570765
View directory record Official record
Conditions
Liver Cirrhosis, Biliary
Interventions
Placebo, Obeticholic Acid (OCA)
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
4
States / cities
Detroit, Michigan • Houston, Texas • Richmond, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 18, 2026, 3:12 PM EDT
Completed Phase 2 Interventional Results available

Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC)

NCT02177136
View directory record Official record
Conditions
Primary Sclerosing Cholangitis (PSC)
Interventions
Obeticholic Acid (OCA), Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
33
States / cities
Phoenix, Arizona • Sacramento, California • Aurora, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Oct 18, 2026, 3:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Hepatic Impairment Trial of Obeticholic Acid

NCT01904539
View directory record Official record
Conditions
Hepatic Impairment
Interventions
obeticholic acid 10 mg
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 24, 2013 · Synced Oct 18, 2026, 3:12 PM EDT
Terminated Phase 4 Interventional Results available

Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis

NCT02308111
View directory record Official record
Conditions
Liver Cirrhosis, Biliary
Interventions
Obeticholic Acid (OCA), Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
43
States / cities
Phoenix, Arizona • Los Angeles, California • Rialto, California + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Oct 18, 2026, 3:12 PM EDT
Terminated Phase 2 Interventional Results available

Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH)

NCT02039219
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
Placebo, 10 mg Obeticholic Acid (OCA)
Drug
Lead sponsor
Naga P. Chalasani
Other
Eligibility
21 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
4
States / cities
Indianapolis, Indiana • Rochester, Minnesota • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Oct 18, 2026, 3:12 PM EDT
Terminated Phase 2 Interventional Results available

Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)

NCT00550862
View directory record Official record
Conditions
Liver Cirrhosis, Biliary
Interventions
INT-747, Ursodeoxycholic Acid (URSO), Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
13
States / cities
Gainesville, Florida • Miami, Florida • Boston, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Oct 18, 2026, 3:12 PM EDT
Terminated Phase 4 Interventional Results available

Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment

NCT03633227
View directory record Official record
Conditions
Liver Cirrhosis, Biliary
Interventions
Obeticholic Acid (OCA), Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
11
States / cities
Rialto, California • Sacramento, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2022 · Synced Oct 18, 2026, 3:12 PM EDT